Humana Inc (NYSE:HUM) SVP Cynthia H. Zipperle sold 1,196 shares of the firm’s stock in a transaction dated Friday, March 9th. The shares were sold at an average price of $273.33, for a total transaction of $326,902.68. Following the completion of the transaction, the senior vice president now directly owns 7,771 shares in the company, valued at approximately $2,124,047.43. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
Shares of Humana Inc (HUM) traded down $4.29 during trading hours on Monday, hitting $268.21. 967,774 shares of the company were exchanged, compared to its average volume of 1,110,984. The firm has a market cap of $37,010.00, a P/E ratio of 15.17, a price-to-earnings-growth ratio of 1.48 and a beta of 0.95. The company has a quick ratio of 1.85, a current ratio of 1.85 and a debt-to-equity ratio of 0.48. Humana Inc has a 1-year low of $203.48 and a 1-year high of $293.35.
Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, February 7th. The insurance provider reported $2.06 earnings per share for the quarter, beating analysts’ consensus estimates of $2.00 by $0.06. The business had revenue of $13.19 billion for the quarter, compared to the consensus estimate of $13.14 billion. Humana had a net margin of 4.55% and a return on equity of 16.13%. Humana’s revenue for the quarter was up 2.4% on a year-over-year basis. During the same period last year, the company posted $2.34 EPS. equities analysts anticipate that Humana Inc will post 13.81 earnings per share for the current year.
Humana announced that its Board of Directors has authorized a share repurchase plan on Thursday, December 14th that permits the company to repurchase $3.00 billion in outstanding shares. This repurchase authorization permits the insurance provider to purchase shares of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board of directors believes its stock is undervalued.
Several research analysts have recently issued reports on HUM shares. Zacks Investment Research raised shares of Humana from a “hold” rating to a “buy” rating and set a $294.00 target price on the stock in a research note on Monday, February 12th. Jefferies Group raised shares of Humana from a “hold” rating to a “buy” rating and set a $221.00 target price on the stock in a research note on Friday, January 12th. Goldman Sachs Group started coverage on shares of Humana in a research note on Wednesday, January 3rd. They issued a “buy” rating and a $305.00 target price on the stock. Cowen reaffirmed a “buy” rating and issued a $285.00 target price on shares of Humana in a research note on Wednesday, December 13th. Finally, Cantor Fitzgerald reaffirmed a “hold” rating and issued a $250.00 target price on shares of Humana in a research note on Wednesday, February 7th. Seven analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $270.47.
A number of hedge funds have recently made changes to their positions in the business. Cambridge Investment Research Advisors Inc. raised its holdings in Humana by 18.8% during the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 3,372 shares of the insurance provider’s stock worth $836,000 after buying an additional 534 shares during the period. Certified Advisory Corp acquired a new stake in Humana during the 4th quarter worth approximately $109,000. Colonial Trust Advisors acquired a new stake in Humana during the 4th quarter worth approximately $13,780,000. Xact Kapitalforvaltning AB raised its holdings in Humana by 6.9% during the 4th quarter. Xact Kapitalforvaltning AB now owns 24,981 shares of the insurance provider’s stock worth $6,197,000 after buying an additional 1,606 shares during the period. Finally, OLD Mutual Customised Solutions Proprietary Ltd. raised its holdings in Humana by 41.8% during the 4th quarter. OLD Mutual Customised Solutions Proprietary Ltd. now owns 9,159 shares of the insurance provider’s stock worth $2,272,000 after buying an additional 2,700 shares during the period. Hedge funds and other institutional investors own 97.85% of the company’s stock.
WARNING: This article was published by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.americanbankingnews.com/2018/03/12/insider-selling-humana-inc-hum-svp-sells-1196-shares-of-stock.html.
Humana Company Profile
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.